Purpose: To provide the practicing clinical ophthalmologist with an update of pertinent glaucoma literature published over the past 12 months.
M any significant and clinically impactful advances were made for glaucoma diagnoses and treatment during the 2011 to 2012 academic calendar year. Whereas improved statistical methodologies made impacts on automated perimetry, studies using spectral-domain optical coherence tomography (SD-OCT) continued to provide useful insights for optic nerve imaging. On the therapeutic side, intraocular pressure (IOP) remained the predominant (but not solitary) metric of therapeutic success. Many prospective studies in trabeculectomy and glaucoma drainage device implantation were performed, representing years of planning and countless hours of executing studies that will guide future clinical decisions.
This review highlights only a selected number of articles that appeared in the English language literature, primarily involving human subjects. Included articles were listed in PubMed between July 1, 2011, and June 30, 2012. Large, prospective, randomized trials were given preference for inclusion. The overriding consideration in the selection was the desire to include clinically relevant, novel, and potentially important original research.
AUTOMATED PERIMETRY
Although standard automated perimetry (SAP) has been the clinical standard for many years, alternative technologies have been proposed to detect glaucoma at earlier stages and with greater sensitivity. In a study of 132 eyes (92 with glaucoma and 37 normal), Liu et al 1 compared SAP, frequencydoubling technology (FDT) perimetry, and short-wavelength automated perimetry (SWAP) for glaucoma detection. When glaucoma was defined with SD-OCT retinal nerve fiber layer (RNFL) thickness deviation maps, FDT had the highest sensitivity (69%), followed by SAP (68%), and then SWAP (59%). When a fixed specificity of 90% was chosen, there were significant differences in sensitivities between Matrix FDT perimetry and Swedish interactive threshold algorithm SWAP, whereas SAP and FDT were not significantly different. 1 Park et al 2 sought to characterize 122 patients presenting with either an initial parafoveal scotoma or nasal step greater than 10 degrees from fixation. They found that compared with patients with nasal steps, those with parafoveal scotomas had lower untreated maximum IOPs [mean (SD), 21.6 (4.5) vs 28.3 (9.6) mm Hg; P G 0.001], more optic disc hemorrhages, and more systemic comorbidities such as hypotension, migraines, Raynaud phenomenon, and sleep apnea. Refractive error did not differ between the 2 groups. 2 To compare the pattern of damage seen in patients with chronic angle-closure glaucoma (CACG) and those with primary open-angle glaucoma (POAG), Nouri-Mahdavi et al 3 designed a retrospective cross-sectional study encompassing 32 eyes from 32 patients with CACG and race-matched and field loss-matched eyes with POAG. They found that patients with CACG were more hyperopic [mean (SD), 0.6 (0.4) vs j1.4 (0.5) D; P G 0.001] and had higher IOPs [mean (SD), 15 .8 (0.8) vs 13.9 (0.9) mm Hg; P = 0.015]. Eyes with PACG had smaller cup areas, cup volumes, and mean cup depths, with larger rim/ disc area ratios (P G 0.05). The average mean deviation (MD) on visual field testing was j5.1 dB in both groups, although field defects were less likely to involve paracentral points in CACG eyes (47% vs 72%, P = 0.04). 3 The Ocular Hypertension Treatment Study Group assessed the global rates of visual field deterioration in 2609 eyes of 1379 participants who were followed up for more than 5 years or had more than 10 reliable visual fields. Although fields progressed very slowly on average [mean (SD), j0.08 (0.20) dB/y], the 359 patients with POAG progressed more quickly [mean (SD), j0.26 (0.36) dB/y]. Patients meeting POAG end points based on visual field criteria (n = 74) worsened more rapidly [mean (SD), j0.29 (0.31) dB/y] than those who only met criteria on the basis of optic disc changes [n = 158; mean (SD), j0.12 (0.19) dB/y], whereas eyes that met a POAG end point for both criteria (n = 127) deteriorated more rapidly than any other group [mean (SD), j0.42 (0.46) dB/y]. Interestingly, rates of global visual field change did not differ based on initial randomization to treatment or observation. 4 Medeiros et al 5 incorporated risk factor informationV including IOP, central corneal thickness (CCT), and history of progressive disc damageVinto a Bayesian model to predict future rates of visual field progression and to assess whether the addition of risk factor information could improve upon the standard ordinary least squares linear regression technique for predicting progression. They found that the mean square error of predictions formulated by their model was significantly lower than that of the linear regression technique, indicating that the incorporation of structural and risk factor information into the estimation of glaucomatous visual field progression resulted in better estimates of slopes of visual field change. 5 To investigate the use of frequent visual field testing, Nouri-Mahdavi et al 6 designed a retrospective study composed of 468 eyes from 381 patients in which they compared the sensitivities of high frequency (910 reliable fields during 3 years of follow-up) and low frequency (exclusion of every other field test starting at year 1) in the detection of glaucoma progression. They found that high-frequency data sets were more likely to detect progression using both MD [hazards ratio (HR), 1.69; 95% confidence interval (CI), 1.36Y2.10] and pointwise linear regression criteria (HR, 1.52; 95% CI, 1.21Y1.90). Furthermore, high-frequency sets were also more likely to detect improvement when pointwise linear regression criteria were used (HR, 2.27; 95% CI, 1.43Y3.62). 6 
OPTIC NERVE PHOTOGRAPHY AND IMAGING
Ren et al 7 studied the relationship between the translaminar cribrosa pressure gradient (IOPYlumbar CSF pressure) and neuroretinal rim area (RA) in 52 patients with high-pressure glaucoma, normal-pressure glaucoma, or ocular hypertension. They found that both neuroretinal RA (P = 0.006, correlation coefficient r = j0.38) and mean visual field defect (P = 0.008, r = 0.38) were more tightly associated with the difference in trans-laminar cribrosa pressure than either IOP or lumbar CSF pressure alone. 7 Similarly, Resch et al 8 assessed choroidal and optic nerve head (ONH) blood flow, as well as retinal blood velocities and retinal vessel diameters, in a group of 103 patients to investigate the relationship between ocular blood flow and ONH morphology. They found that, of the parameters tested, blood flow to the ONH was most tightly correlated with morphology and visual field defects. 8 In the population-based Beijing Eye Study, 77 patients with open-angle glaucoma underwent baseline optic disc photography in 2001 and subsequent follow-up imaging in 2006. Although a smaller RA, presence and progression of peripapillary atrophy, disc hemorrhage, and IOP were associated with progression in a univariable analysis of the 21% of eyes that demonstrated structural progression, a smaller RA at baseline was the only significant risk factor found with multivariable analysis. Risk factors not associated with progression included corneal thickness, refractive error, blood and perfusion pressures, and diabetes mellitus. 9 Until recently, there had been no evidence that SD-OCT was superior to time-domain OCT. To determine whether the increased resolution of SD-OCT confers advantages over timedomain OCT, Leung et al 10 followed up 128 eyes from 81 patients with glaucoma using both techniques every 4 months for a period spanning at least 24 months. The SD-OCT system demonstrated lower measurement variability and detected significantly more cases of progression than the time-domain system. Although the 2 platforms showed poor agreement in detecting progression, SD-OCT demonstrated better agreement with visual field testing for progression. 10 Although previous studies have reported that older patients tend to have thinner RNFLs when populations are viewed in cross-section, Leung et al compiled a cohort of patients who were imaged longitudinally using SD-OCT to demonstrate that RNFL thins at a rate of approximately j0.52 Km/y. 11 Local RNFL segmentation errors can interfere with the ability of OCT systems to provide clinically useful information. Although global signal strength is used to determine the overall quality of OCT acquisition, Folio et al 12 hypothesized that local signal scan quality values, reflecting the strength of individual A-scans, could also be useful. Using customized software, the investigators determined that a combination of variables, including local and global signal strength, could be used to predict segmentation errors. 12 Although multiple B-scan averaging is often applied to RNFL thickness measurements taken with SD-OCT, Ye et al 13 showed that this practice may not decrease measurement variability. They found that regardless of whether 2, 8, or 16 B-scans were averaged, intraclass correlation coefficients (ICCs), coefficients of variation, and image quality scores were all similar. 13 Mwanza et al 14 used Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, CA) to reproducibly segment and measure macular retinal ganglion cell-inner plexiform layer (GCIPL) thickness and found that this technique was able to successfully segment the GCIPL in 50 of 51 patients. When comparing repeat measurements, all ICCs ranged between 0.94 and 0.98. The authors concluded that GCIPL thickness can be measured with SD-OCT with excellent intervisit reproducibility, which could allow for trend-based analysis over time. 14 Based on these findings, Mwanza et al 15 then performed a study in which 58 patients with early glaucoma and 99 agematched controls underwent Cirrus high-definition OCT ganglion cell analysis to assess the diagnostic use of macular GCIPL thickness. Compared with traditionally used parameters such as peripapillary RNFL thickness and ONH measurements, they found that GCIPL can also be used reliably to detect early glaucomatous changes. 15 Grewal et al 16 used GDxYenhanced corneal compensation (GDxECC) to assess the rate of RNFL loss in progressing versus nonprogressing glaucoma suspect and glaucomatous eyes, while implementing the Early Manifest Glaucoma Trial criterion, SAP Visual Field Index, and Progressor software (Medisoft, Ltd., Leeds, United Kingdom) to define functional progression. Among the 53 eyes enrolled in their prospective study, the annual rate of RNFL loss measured using GDxECC was significantly greater in progressing versus nonprogressing eyes, irrespective of the criteria used to determine functional progression. 16 Given that some SD-OCT platforms offer posterior pole asymmetry analysis in addition to circumpapillary RNFL (cpRNFL) thickness measurements, Seo et al 17 compared SD-OCT findings in 84 patients with localized, wedge-shape RNFL defects by red-free RNFL photography with that of 122 normal eyes to determine the sensitivity and specificity of each technique. The sensitivity and specificity of posterior pole asymmetry analysis were 83.3% and 92.6%, respectively, which were similar to that of cpRNFL thickness (85.7% and 95.1%). 17 Maul et al 18 designed a cross-sectional study consisting of 74 patients with glaucoma and glaucoma suspects and used SD-OCT to estimate average macular and peripapillary choroidal thicknesses. The group found that the macular choroid was significantly thinner in the setting of elongated eyes (22 Km per mm longer), increased age (31 Km thinner per decade older), lower diastolic ocular perfusion pressure (26 Km thinner per 10 mm Hg lower), and thicker central corneas (6 Km per 10 Km thicker). Furthermore, they did not find any significant difference in macular or peripapillary choroidal thickness between patients with glaucoma and glaucoma suspects. They also did not find any clear association between absolute thickness and damage severity. 18 Researchers from the Chinese University of Hong Kong used swept-source OCT to obtain anterior chamber angle measurements and found good reproducibility, with ICCs of 0.83 or greater. They found that differences in iris thickness, angle width, and measurement location were associated with increased variance of angle measurements. 19 To identify factors affecting the anterior chamber depth (ACD), Sng et al 20 performed a cross-sectional study consisting of 1060 patients who underwent anterior segment OCT. They found that the mean (SD) ACD was 3.24 (0.35) mm, which was most heavily influenced by the lens vault (R 2 = 0.582, P G 0.001) and the posterior corneal arc length (partial R 2 = 0.186, P G 0.001), which together accounted for 76.8% of ACD variability. Neither axial length nor lens thickness was well correlated with ACD. 20 
STRUCTURE AND FUNCTION
To combine structural and functional measurements and to allow for the detection of glaucomatous progression, Medeiros et al 21 developed a Bayesian model to reflect changes in SAP, stereophotographs of the optic disc, and scanning laser polarimetry. Compared with the traditionally implemented ordinary least-squares regression method, this model was more sensitive in the detection of glaucoma progression (22.8% vs 12.8%, P G 0.001) and also more effective at detecting progression based on analysis of optic disc stereophotographs (74% vs 37%, P = 0.001). 21 Medeiros et al 22 also developed a combined index of structure and function based on the estimated loss of retinal ganglion cells, as reflected in the difference between estimated and expected retinal ganglion cell numbers, to stage and detect glaucomatous damage. In their observational study encompassing 333 glaucomatous eyes and 330 healthy eyes, they found statistically significant differences in the combined index of structure and function between patients with perimetric glaucoma (41%), those with preperimetric glaucoma (17%), and healthy participants. In addition, the combined index of structure and function was able to distinguish between early, moderate, and advanced stages of disease. 22 Nilforushan et al 23 investigated the structure-function relationship between SD-OCT and standard achromatic perimetry, by examining 136 eyes of 97 patients with early glaucoma and glaucoma suspects. They found that the mean (SD) RNFL thickness in the patients was 85.6 (5.7) Km, with a mean (SD) RA of 1.0 (0.3) mm 2 and MD of j1.3 (1.9) dB. Furthermore, global RA was more highly correlated with MD than with RNFL thickness (P = 0.002), with the highest correlations present between the superonasal visual field cluster and inferotemporal RA (R 2 = 0.26; 95% CI, 0.15Y0.40) or inferotemporal RNFL thickness (R 2 = 0.24; 95% CI, 0.13Y0.37). A greater degree of correlation was seen with the decibel scale than with the 1/L scale, although linear correlations were seen on both. 23 
INTRAOCULAR PRESSURE
To better define 24-hour IOP dynamics, Wang et al 24 created a study composed of 47 patients with untreated POAG who underwent serial IOP checks using Goldmann applanation tonometry at 10 AM, 2 PM, 6 PM, 10 PM, 2 AM, and 6 AM over a single 24-hour period. They found that 39 of these patients (83.0%) had a peak IOP of 21 mm Hg or less, with a mean (SD) of 18.4 (3.7) mm Hg. Peak IOPs tended to occur between 6 and 10 AM (76.5%), whereas troughs were seen most commonly between 10 PM and 2 AM (70.2%). The overall mean (SD) IOP over the 24-hour monitoring period was 15.4 (3.1) mm Hg, and the mean (SD) fluctuation was 6.0 (2.2) mm Hg. In the 22 patients with unilateral disease, there was no significant difference between mean 24-hour IOP, peak IOP, trough IOP, or IOP fluctuation between the glaucomatous and nonglaucomatous eye (P 9 0.05). 24 Mansouri et al 25 compared the change in IOP between younger (ages 18Y25 years) and older (ages 52Y71 years) subjects in sitting and supine positions over a 24-hour period. Both groups of patients experienced an IOP increase of 5 mm Hg when supine during diurnal and nocturnal periods, without any significant difference between age groups. The phase timing (simulated peak) of 24-hour IOP was significantly delayed for the older subjects in both the seated and supine positions. 25 Although mean diurnal IOP is the only proven target for pressure reduction in glaucoma, investigators from the Collaborative Initial Glaucoma Treatment Study also linked glaucoma progression to other IOP parameters, including the maximum, mean, SD, and range of IOP. Using the visual field MD at 3 to 9 years postrandomization, investigators found that the maximum, SD, and range of IOP were all significantly associated with substantial worsening of MD in both medically and surgically treated patients. Of note, patients of black race, with higher baseline IOPs, and from specific study centers were more likely to have greater maximum, SD, and range of IOP. 26 To determine whether IOP reduction is symmetric between paired eyes initiated on IOP-lowering therapy, Liu et al 27 analyzed a database of patients between the ages of 41 and 79 years with POAG or ocular hypertension who were initiated on bilateral IOP-lowering therapy. These patients underwent 24-hour IOP assessment in both eyes before and after initiation of therapy. The group found that paired eyes had IOP reductions differing by 3 and 2 mm Hg or more in at least 20% and 36% of cases, respectively. The coefficients of determination for patients initiated on monotherapy ranged from 0.24 to 0.37, and the authors ultimately concluded that the response to IOPlowering therapy is often asymmetric. 27 Lavanya et al 28 assessed 471 patients with narrow angles both before and 1 hour after pupil dilation with 1% tropicamide and pretreatment with oral acetazolamide to evaluate the risk of acute angle closure and changes in IOP. Of the 471 patients in the study, 3 developed acute angle closure within 6 hours of dilation. Twenty-two patients (4.67%) developed a postdilation increase in IOP of 5 mm Hg or greater in either eye, whereas 6 patients (1.27%) had an IOP increase of 8 mm Hg or greater. Four patients (0.85%) had a postdilation IOP of more than 25 mm Hg in either eye. Lower modified Shaffer grade and predilation IOP were both significant risk factors for IOP increase after dilation. 28 Jiang et al 29 investigated the change in IOP after laser peripheral iridotomy through a prospective randomized controlled study encompassing 734 patients who underwent iridotomy in 1 randomly selected eye. They found that the mean (SD) IOP 1 hour after treatment was 17.5 (4.7) mm Hg in treated eyes, compared with 15.2 (2.6) mm Hg in untreated contralateral eyes, whereas 2 weeks after treatment, these values were 15.6 (3.4) mm Hg in treated eyes and 15.1 (2.7) mm Hg in controls (P G 0.001). Intraocular pressure spikes, which were defined as an elevation in IOP of 8 mm Hg or greater over baseline, were seen in 9.8% of patients 1 hour after treatment and in 0.82% of patients 2 weeks after iridotomy. Four of the eyes in the study (0.54%) had an immediate posttreatment IOP of 30 mm Hg. The incidence of IOP spikes was correlated with increased amounts of total laser energy during iridotomy and anatomically shallow central anterior chambers. 29 
CORNEAL THICKNESS AND BIOMECHANICS
Given that CCT has been shown to influence the accuracy of IOP measurements and relate to the risk of incident POAG, the Ocular Hypertension Treatment Study Group sought to determine the use of adjusting IOP values for CCT before assessing the risk of POAG in patients with ocular hypertension. When the authors substituted CCT-adjusted IOP values using 5 different correction formulae for unadjusted IOP, the C-statistics ranged from 0.75 to 0.77, which was similar to when IOP was not adjusted (0.77). Central corneal thickness remained a significant term in all models, indicating that IOP and CCT can be used independently to predict glaucoma risk without having to adjust IOP for CCT. 30 Birt et al 31 followed up 75 subjects for 24 weeks to investigate whether the IOP-lowering effect of topical prostaglandin analogs was influenced by CCT. Although the observed effect was weak, the authors found that patients with higher baseline IOPs experienced greater reduction on treatment. Furthermore, for every 10 Km increase in CCT, there was 0.3 mm Hg less of an IOP decrease from baseline. 31 Given that corneal hysteresis (CH) has been associated with both glaucoma and glaucomatous progression, researchers at the Hamilton Glaucoma Center sought to determine the relationship between CH and glaucoma severity using visual field MD and RNFL thickness measurements, in conjunction with either GDxECC or SD-OCT. In general, the relationships were weak and attenuated in multivariable analyses. Although CH was positively associated with MD (R 2 = 0.10, P G 0.01), in the multivariable analysis adjusting for CCT, age, and axial length, the association between CH and MD lost significance (P = 0.77), as did any relationships between CH and RNFL measured with either GDx or SD-OCT. 32 Huang et al 33 followed up 31 patients undergoing trabeculectomy and examined them for changes in axial length, CH, and IOP both 1 day and 1 week after surgery to determine which factors were associated with postoperative changes in axial length. At the 1-week postoperative mark, IOP was reduced from [mean (SD)] 21.4 (9.3) mm Hg to 11.0 (4.4) mm Hg (P G 0.001), and axial length decreased in 30 of 31 patients, from a baseline of [mean (SD)] 22.99 (0.90) mm to 22.74 (0.9) mm (P G 0.001). Resultant IOP reduction from the surgery and lower baseline CH were both associated with a greater reduction in axial length. 33 De Moraes et al 34 recently examined factors associated with visual field progression in 153 patients who had taken more than 5 visual field tests (mean, 8.5) over an average follow-up period of 5 years. Compared with eyes without progression, the investigators found that progressing eyes had lower CCT [mean (SD), 525.0 (34.2) Km vs 542.3 (38.5) Km; P = 0.04] and lower CH [mean (SD), 7.5 (1.4) mm Hg vs 9.0 (1.8) mm Hg; P G 0.01]. In a multivariable analysis, peak IOP, age, and CHVbut not CCTVwere significantly associated with progression. The study provided rationale for the investigation of CH in prospective studies of glaucomatous progression. 34 To assess the effects of aging and glaucoma on posterior scleral structure, Coudrillier et al 35 designed an experiment in which scleral specimens from 22 normal eyes and 11 glaucomatous eyes were placed into an inflation chamber and used to assess morphologic changes in response to increasing pressures. They found that older normal eyes tended to have thinner sclera with stiffer responses, whereas older glaucomatous eyes (age range, 75Y93 years) were thicker than normal. Furthermore, glaucomatous eyes generally exhibited a stiffer meridional response in the peripapillary sclera. There was no significant difference in the midposterior sclera among the eyes examined. 35 
PHARMACOLOGIC IOP LOWERING
Given the high prevalence of normal tension, Nakano et al 36 Ma et al 37 performed a 5-year retrospective, multicenter analysis of Korean patients with normal tension glaucoma, with progression defined by the Advanced Glaucoma Intervention Study visual field criteria. They did not find any significant differences between stable and progressing patients in terms of mean IOP or proportion of patients with IOPs above 15 mm Hg. However, progressing patients may have been treated more aggressively because the baseline number of glaucoma medications and visual field score, as well as the mean, peak, and SD of IOP, were all significantly associated with glaucoma progression in a multivariable analysis (P G 0.01). 37 Chabi et al 38 performed a 12-week randomized, doublemasked, multicenter clinical trial investigating the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Intraocular pressure reduction was similar between the 2 groups, meeting the study criteria for noninferiority. In the tafluprost group, IOP was reduced from an untreated baseline of 23.8 to 26.1 mm Hg to 17.4 to 18.6 mm Hg at 12 weeks. Although the incidence of ocular pain, stinging, irritation, and pruritis was similar between groups, the tafluprost group experienced more hyperemia (4.4% vs 1.2%, P = 0.016). 38 With the availability of generic latanoprost, there has been interest from the clinical community regarding the efficacy of generic latanoprost formulations. As such, Allaire et al 39 performed a 6-week multicenter, randomized, investigator-masked, parallel-group study consisting of 266 patients with ocular hypertension or glaucoma, who were randomized to treatment with either latanoprost 0.005% (Bausch & Lomb, Rochester, NY) or Xalatan (latanoprost 0.005%, Pfizer, Inc., New York, NY). The Bausch & Lomb formulation of latanoprost met the predefined definition of equivalence to Xalatan. 39 In an effort to better understand the financial ramifications of glaucoma therapy, investigators at Semmelweis University in Budapest, Hungary, sought to determine the direct costs of therapy over 5 years within a cohort initiated on either prostaglandin or timolol monotherapy. The authors followed up 271 patients (166 on a prostaglandin and 105 on timolol) and found that the cost per month per patient in German prices over 5 years was [mean (SD)] $45.47 ($12.61) for prostaglandins and $31.50 ($15.47) for timolol (P G 0.001). However, the timolol group exhibited higher IOPs [mean (SD), 17.7 (2.9) vs 16.5 (3.0) mm Hg; P G 0.001], a higher rate of glaucoma progression (P = 0.04), and a greater need to add or change medications (P G 0.001) than those on treatment with prostaglandins. 40 To examine the effects of eyelid closure on IOP after prostaglandin instillation, Maul et al 41 performed a randomized study in which 51 patients on chronic bilateral prostaglandin monotherapy closed one of their eyelids for either 1 or 3 minutes after the administration of drops. The study found that eyelid closure after prostaglandin instillation provided only 0.24 mm Hg (j0.7 to 1.2) of additional IOP reduction in these patients, which was not statistically significant (P = 0.61). 41 
COMPLIANCE
In their randomized study consisting of 127 patients categorized into adequate, marginal, and inadequate literacy groups, Muir et al 42 found that patients within all groups who received glaucoma education went fewer days without glaucoma medicine, with the most pronounced effect seen in patients categorized into the inadequate literacy group.
Similarly, Gray et al 43 described the effect of individualized assessments on compliance, self-reported adherence, and IOP fluctuation in patients starting medical ocular hypotensive therapy. In their single-masked randomized control study, patients who received personalized assessments before and during treatment exhibited better compliance, self-reported adherence, and a better understanding of glaucoma compared with patients in the control arm of the study. Furthermore, these control patients exhibited greater IOP fluctuation and underwent more changes in management than the treatment group did at 24 months. 43 Dreer et al 44 sought to determine risk factors for poor medication adherence to topical glaucoma therapy by using an electronic dose monitor (Travatan Dosing Aid; Alcon Laboratories, Inc, Fort Worth, Tex). Patient age, total number of other eye diseases, and race were all significantly associated with poor adherence, which was defined as properly taking the prescribed number of drops within 3 hours of the prescribed dosing time. Those who were less adherent were more likely to be of African descent. 44 
GLAUCOMA LASER THERAPY
Although selective laser trabeculoplasty (SLT) may have theoretical advantages over argon laser trabeculoplasty (ALT), there is a paucity of long-term head-to-head data. As such, investigators from the University of Ottawa Eye Institute reported their long-term follow-up results from a prospective randomized clinical trial obtained from the practices of 3 ophthalmologists in which 176 eyes of 152 patients with uncontrolled IOP on maximal tolerated medical therapy were randomized to undergo either SLT or ALT. After 5 years, both modalities demonstrated similar efficacy, with SLT reducing IOP by [mean (SD)] 7.4 (7.3) mm Hg and ALT reducing IOP by [mean (SD)] 6.7 (6.6) mm Hg. In addition, medication use and failure rates were similar between the 2 groups, with approximately 50% from each group failing treatment by 2 years. 45 Heijl et al 46 analyzed IOP reduction after ALT in the Early Manifest Glaucoma Trial and also examined factors impacting treatment efficacy in a group of 127 patients they followed up for up to 8 years. Argon laser trabeculoplasty resulted in [mean (SD)] 2.8 (3.9) mm Hg of IOP reduction from a baseline pressure of [mean (SD)] 18.1 (3.9) mm Hg. Of note, for each 3Ymm Hg increase in baseline pressure, there was an additional 2 mm Hg of IOP reduction. Furthermore, efficacy varied among surgeons, with mean IOP reduction after ALT ranging from 5.8 to j1.3 mm Hg, depending on the surgeon performing the procedure. 46 
CATARACT EXTRACTION AND IOP REDUCTION

Mansberger et al 47 investigated changes in IOP seen in 63 eyes within the observation arm of the Ocular Hypertension
Treatment Study after cataract surgery. Although the mean IOP remained to be 23 to 24 mm Hg in the 743 control eyes that did not undergo surgery, postoperative IOP in the cataract group was significantly reduced from a mean (SD) baseline of 23.9 (3.2) mm Hg down to 19.8 (3.2) after surgery (P G 0.001). The effect, which amounted to a 16.5% reduction in IOP, was sustained for 36 months, with 39.7% of patients experiencing at least a 20% reduction in IOP. Higher baseline IOP was associated with a greater IOP reduction after the procedure. 47 Investigators from the Vanderbilt Eye Institute reviewed the records of patients with open-angle glaucoma or ocular hypertension who underwent unilateral phacoemulsificationV with the fellow eye remaining phakic for at least 3 years afterwardVto determine the IOP-lowering effect of cataract extraction. Preoperative IOPs were similar between study eyes [mean (SD), 15.66 (3.33) mm Hg] and observation eyes [mean (SD), 15.64 (4.23) mm Hg]; however, in counterdistinction to the findings reported in the Ocular Hypertension Treatment Study, the IOP in both groups of eyes fell to [mean (SD)] 14.68 (3.44) mm Hg and 14.68 (2.68) mm Hg at 3 years (P = 1.00), respectively. The use of IOP-lowering medications was similar between both groups postoperatively. 48 Lewis et al 49 reported 3-year safety and efficacy data for 157 patients who underwent either canaloplasty or combined cataract extraction and canaloplasty. In the canaloplasty procedure, a scleral flap was created, and the surgeon subsequently used a flexible microcatheter via ab externo (transconjunctival, transscleral) approach to viscodilate the full circumference of Schlemm canal, after which a 10-0 Prolene trabecular-tensioning suture (Ethicon, Inc, Somerville, NJ) was placed.
At 3 years, overall IOP fell to [mean (SD)] 15.2 (3.5) mm Hg from a mean preoperative IOP of 23.8 mm Hg, and the mean (SD) use of glaucoma medications fell from 1.8 (0.9) to 0.8 (0.9). These figures correspond to an 8.6Ymm Hg (36%) reduction from baseline. On the other hand, the mean (SD) IOP in eyes that underwent both cataract and canaloplasty fell to 13.6 (3.6) mm Hg, and the number of medications required postoperatively decreased to [mean (SD)] 0.3 (0.5). In this group, the mean (SD) baseline IOP was 23.5 (5.2) mm Hg (42% IOP reduction), and patients were on [mean (SD)] 1.5 (1.0) medications before surgery. The only significant complications reported were cataract formation in 12.7% of eyes and transient IOP elevation in 6.4%. 49 
SECONDARY GLAUCOMAS
Is pars plana vitrectomy associated with POAG? Chang et al 48 investigated the issue of open-angle glaucoma after vitrectomy using a retrospective cohort and matched case-controlled study consisting of 285 vitrectomized eyes. They found that 11.6% of patients (n = 33) developed glaucoma within 6 months of vitrectomy. The only variable significantly associated with the development of glaucoma was cataract extraction (odds ratio, 16.4; 95% CI, 2.1Y127.4; P = 0.007). In phakic eyes, the incidence of glaucoma was 1.4%, whereas the incidence in nonphakic eyes was 15%. As a result, the authors concluded that patients with lens extraction performed before or during vitrectomy should be carefully monitored for the development of open-angle glaucoma and that a discussion regarding the risk of glaucoma should be part of the informed consent process for some patients requiring vitrectomy. 50 The Multicenter Uveitis Steroid Treatment study, a randomized, controlled, parallel superiority trial carried out at 23 centers and including 255 patients, examined the efficacy of systemic corticosteroids with or without immunosuppressives versus fluocinolone acetonide implants in the treatment of noninfectious intermediate, posterior, and panuveitis. The primary outcome measure, assessed at 24 months, was change in bestcorrected visual acuity from baseline, with secondary outcomes including quality of life, uveitis activity, and complications stemming from both treatment and the disease process itself.
Change in best-corrected visual acuity within the implant and systemic treatment groups was +6.0 and +3.2 letters (P = 0.16), respectively. In addition, patients treated with implants experienced more improvement in vision-related quality of life (+11.4 vs +6.8 units, P = 0.043) and less residual active uveitis (12% vs 29%, P = 0.001). However, eyes receiving implants had a higher risk of cataract surgery (80%; HR, 3.3; P G 0.0001), treatment for elevated IOP (61%; HR, 4.2; P G 0.0001), and glaucoma (17%; HR, 4.2; P = 0.0008). Of note, patients receiving systemic treatment developed more infections requiring treatment (0.60 vs 0.36/person-year, P = 0.034). 51 
GLAUCOMA SURGERY: TRABECULECTOMY
To characterize the success rates and complications of trabeculectomy, Jampel et al 52 compiled a case series of 797 eyes from 634 people who underwent uncombined trabeculectomy surgery between May 2000 and October 2008. They found that success rates 4 years after surgeryVwith or without the use of IOP-lowering eye dropsVwere 72% for achieving IOP of 18 mm Hg or less and 20% or more IOP reduction, 60% for achieving IOP of 15 mm Hg or less and 25% or more reduction, and 44% for achieving IOP of 12 mm Hg or less and 30% or more reduction. Greater success rates were seen in patients of European descent, surgeries using higher concentrations of mitomycin C (MMC), and higher preoperative IOP. The most common complications reported in the study included lenticular opacification (55%), loss of 3 or more Snellen lines of acuity (21%), surgery for bleb-related issues (8.8%), and infection occurring more than 6 weeks after surgery (3.4%). Furthermore, 101 eyes required at least 1 additional surgery because of insufficient IOP control. 52 Similarly, Solus et al 53 compiled a retrospective case series consisting of 439 eyes from 347 patients who underwent trabeculectomy between May 2000 and October 2008 to compare the success rates and complications between limbus-based and fornix-based approaches. They found that there was no statistically significant difference in achieving predetermined IOP criteria between the 2 techniques. However, the group found that the limbus-based approach generally produced higher, avascular blebs and was also associated with a higher rate of infections during the first 4 years after surgery. When they occurred, bleb leaks were seen later with the limbal approach compared with the forniceal approach (2.1 vs 1.0 years). Complications more commonly associated with the fornix-based approach included symptomatic hypotony and an increased frequency and earlier requirement for cataract surgery. 53 Although there are many variations for the trabeculectomy technique, recent studies have prospectively randomized trabeculectomy patients to elucidate techniques that enhance success rates. For instance, researchers from the Singapore Eye Research Institute performed a prospective, randomized, controlled trial comparing a sustained-delivery formulation of hyaluronic acid (HA) mixed with 5-fluorouracil (5FU) versus 5FU alone as an adjunct to bleb needling for failed trabeculectomy. The primary outcome measure was an IOP of less than 15 mm Hg at 3 months without any medications, whereas secondary outcomes included bleb appearance and need for additional procedures. At 3 months, both procedures resulted in an IOP decrease of roughly 6.0 mm Hg without any significant difference between groups, although the 5FU group required more repeat needling than the HA-5FU group (50.0% vs 12.0%, P = 0.004). 54 In addition, Husain et al 55 retrospectively evaluated data from a prospective trial in which 235 patients with glaucoma underwent trabeculectomy and were randomized to receive either intraoperative 5FU or placebo to determine whether the timing of cataract extraction was associated with impaired trabeculectomy function. The authors defined failure as IOP of more than 21 mm Hg on 2 consecutive visits spaced 3 to 4 months apart. Over a mean follow-up period of 60 months, 124 patients (52.7%) underwent cataract extraction. Less time from trabeculectomy to cataract surgery was associated with less time to trabeculectomy failure (HR, 1.73; 95% CI, 1.05Y2.85; P = 0.03). Patients with open-angle glaucoma were approximately 75% more likely to experience trabeculectomy failure than those with CACG. 55 The India Glaucoma Outcomes and Treatment Study randomized 398 adults who are 30 years or older with newly diagnosed glaucoma to trabeculectomy with 5FU or medical therapy. Compared with those assigned for surgery (64%), more of the patients randomized to receive medications (86%) followed through with randomization. Of the patients, 26.1% in the medication group and 43.7% of patients in the trabeculectomy arm underwent cataract extraction with intraocular lens (IOL) placement. Ultimately, IOP was lower in patients randomized to trabeculectomy [mean (SD), 16.3 (5.1) mm Hg] than medication [mean (SD), 18.8 (6.7) mm Hg; P G 0.0001), and cataract surgery also resulted in improved visual acuity. 56 In an effort to determine whether scleral flap size influences trabeculectomy safety and efficacy, Ang et al 57 randomized 41 patients to trabeculectomy with either a standard 4 Â 4-mm scleral flap (n = 20) or 2 Â 2-mm scleral flap (microtrabeculectomy, n = 21). After 24 months, the cumulative probability of failure was 0.28 for standard trabeculectomy [mean (SD) IOP, 12.4 (4.6) mm Hg] and 0.27 for microtrabeculectomy [mean (SD) IOP, 11.5 (3.6) mm Hg], with no significant differences between the 2 study arms. 57 In a prospective randomized trial assessing the efficacy and safety of the Ologen (OLO) implant (Aeon Astron Europe B.V., Leiden, The Netherlands) as adjuvant agent in trabeculectomy compared with MMC (0.2 mg/mL for 2 minutes), Cillino et al 58 followed up a group of patients for 24 months, assessing IOP and bleb elevation via SD-OCT and Moorfields Bleb Grading System. Intraocular pressure was reduced from [mean (SD)] 26.5 (5.2) mm Hg in MMC eyes and 27.3 (6.0) mm Hg in OLO eyes to 16.0 (2.9) mm Hg and 16.5 (2.1) mm Hg, respectively. Success rates were similar at a number of target IOPs, although OLO blebs were higher than those created with MMC. Furthermore, bleb height as assessed by OCT was able to provide some ability in distinguishing successful from unsuccessful blebs. 58 Given that MMC enhances trabeculectomy success rates but may increase long-term complications such as bleb leaks and bleb-related infections, researchers at Rassoul Akram Hospital in Tehran, Iran, randomized 36 eyes from 34 patients undergoing trabeculectomy to adjunctive MMC (0.02% for 3 minutes) or subconjunctival bevacizumab (2.5 mg/0.1 mL). After 7 to 8 months of follow-up, both groups experienced significant IOP lowering, with bevacizumab-treated eyes experiencing IOP reduction from a baseline of [mean (SD)] 21.9 (7.9) mm Hg to 13.6 (3.2) mm Hg and MMC-treated eyes experiencing IOP reduction from 23.3 (4.9) mm Hg to 9.6 (2.7) mm Hg (P G 0.001). Although both groups were using 2.6 medications preoperatively, medication use at the final follow-up visit was [mean (SD)] 0.2 (0.5) in the bevacizumab arm and no medications in the MMC arm. 59 Finally, DahanVthe first surgeon to describe the placement of the Ex-PRESS filtration device beneath a scleral flapVled a prospective, randomized study in which 15 eyes underwent trabeculectomy in one eye and Ex-PRESS implantation under a scleral flap in the other. Trabeculectomy reduced IOP from [mean (SD)] 31.1 (14. 2) mm Hg to 16.2 (1.5) mm Hg, whereas Ex-PRESS (Alcon Inc., Forth Worth, TX) implantation reduced IOP from [mean (SD)] 28.1 (9.0) mm Hg to 15.7 (1.8) mm Hg (P = 0.001). Although both groups were using an average of 3.7 medications at baseline, this figure was reduced to 0.9 after trabeculectomy and 0.3 after Ex-PRESS implantation (P = 0.001). In addition, achievement of IOP between 5 and 18 mm Hg without medications occurred more frequently in the Ex-PRESS group than in the trabeculectomy group (P = 0.0024). postoperative complications were also more frequent following trabeculectomy (33% vs 20%). 60 
GLAUCOMA SURGERY: TUBE SHUNTS
The Ahmed Versus Baerveldt Study is an international, randomized trial performed by 10 surgeons at 7 international sites on 238 patients with inadequately controlled glaucoma refractory to conventional medicinal, laser, and surgical therapy. Patients were randomized to receive either an Ahmed FP7 (Flexible Plate TM ) (n = 124) or Baerveldt-350 (n = 114), with failure defined as an IOP reduction of less than 20% from baseline or an IOP of more than 18 mm Hg or less than 5 mm Hg at 2 consecutive visits occurring after the 3-month postoperative mark. Patients enrolled in the study had a baseline IOP of 31.4 mm Hg and were taking, on average, 3 glaucoma medications, with 37% having undergone a previous trabeculectomy. Roughly half of the patients had open-angle glaucoma, whereas 21% had neovascular glaucoma, and 10% had uveitic glaucoma.
Early postoperative IOPs were lower in the first month with the Ahmed implant than with the Baerveldt device. After 1 year, the mean IOP was 16.5 mm Hg (47% reduction from baseline) in the Ahmed group and 13.8 mm Hg (57% reduction from baseline) in the Baerveldt group (P = 0.001), with slightly fewer glaucoma medications required in the Baerveldt group compared with the Ahmed group (1.2 vs 1.6, P = 0.03). Kaplan-Meier survival plots demonstrated that a higher proportion of patients in the Baerveldt group survived at 1 year compared with the Ahmed group when using the primary criteria (IOP, 5Y18 mm Hg). Most failures occurred because of elevated IOP, and only 1 patient in the Baerveldt arm developed persistent hypotony. Visual acuity was similar between the 2 groups at 1 year.
Complication rates were high in the 2 groups (45% for Ahmed, 54% for Baerveldt; P = 0.19), and more patients in the Baerveldt group required intervention for these complications (26% for Ahmed, 42% for Baerveldt; P = 0.009). In general, the interventions themselves were modest and mostly included anterior chamber reformation, anterior chamber paracentesis, and bleb needling. A few more substantial interventions were required, including cataract extraction, vitrectomy, and tube revision. 61, 62 Gedde et al 63 and the Tube Versus Trabeculectomy Study Group reported 5-year data from their trial of 212 eyes or patients with prior conjunctival surgery who were randomized to receive either a trabeculectomy with MMC (0.4 mg/mL for 4 minutes) or a 350-mm 2 Baerveldt glaucoma implant. Consistent with the study's 1-and 3-year outcome reports, there was a higher failure rate after trabeculectomy with MMC (46.9%) compared with the Baerveldt device (29.8%), although the number of medications used was similar between the 2 groups (1.2 and 1.4, respectively). The need for further surgical IOPlowering intervention was 9% in the Baerveldt group and 29% in the trabeculectomy group (P = 0.025). 63 Early postoperative complications were seen in 21% of the Baerveldt group and 37% of the trabeculectomy group (P = 0.012), whereas late postoperative complications (up to 5 years after surgery) developed in 34% and 36%, respectively (P = 0.81). The need for cataract surgery was similar in both groups, occurring in 43% of phakic trabeculectomy eyes and 54% of phakic Baerveldt eyes. Reoperation for surgical complications, similar between groups, was required in 22% of the Baerveldt group and 18% of the trabeculectomy group. 64 Given that the hypertensive phase after Ahmed glaucoma valve surgery may result in permanently elevated IOP, Yuen et al 65 performed a randomized trial of topical steroids versus nonsteroidal anti-inflammatory drugs in 28 consecutive consenting patients undergoing Ahmed glaucoma valve surgery. Although the number of patients was small, the mean IOP was greater at all postoperative time points in the steroid group, although this difference was only statistically significant at week 4. Wound leak and conjunctival retraction were more common in the ketorolac groupV23% and 13%, respectivelyVthan in the dexamethasone arm (0% and 13%; P = 0.087 and P = 0.016). 65 Given that changes in corneal endothelial cell density may result from glaucoma drainage device implantations, Nassiri et al 65 sought to compare corneal endothelial cell changes 24 months after placement of either an Ahmed valve (New World Medical, Inc, Rancho Cucamonga, Calif ) or a singleplate Molteno implant (Molteno Ophthalmic Ltd, Dunedin, New Zealand). Although the Molteno group showed better postoperative IOP control (P G 0.001), there was no significant difference in corneal endothelial cell density between the groups, with an 11.52% reduction in corneal endothelial cell seen in the Ahmed group and 12.37% in the Molteno group. 66 Given the potential difficulty of IOP control after placement of an aqueous tube shunt, researchers at the Doheny Eye Institute reported an interventional case series investigating the efficacy and safety of endoscopic cyclophotocoagulation in 25 eyes of 25 consecutive glaucoma patients with uncontrolled glaucoma after tube shunt placement. After the application of 360-degree endoscopic cyclophotocoagulation, patients demonstrated a decrease in mean IOP from 24.02 mm Hg to 15.36 mm Hg and a decrease in the number of medications from 3.2 before intervention to 1.5 at the 12-month follow-up visit. 67 
PEDIATRICS
Given that reliable measurements of IOP in children often require sedation or anesthesia, Oberacher-Velten et al 68 performed a prospective study on 72 eyes of 36 children in which a Perkins handheld tonometer was used to check IOP at various time points after administration of oral midazolam and after the induction of general anesthesia. The group found that oral midazolam had minimal effects on IOP at time points up to 30 minutes after administration [mean (SD), 11.2 (0.3) mm Hg before sedation, 10.9 (0.2) mm Hg at 15 minutes, and 10.7 (0.3) mm Hg at 30 minutes]. On the other hand, induction of general anesthesia induces a statistically significant IOP decline at 5 and 15 minutes. 68 Girkin et al 69 recently reported the efficacy of circumferential trabeculotomy using an illuminated microcatheter for congenital glaucoma on 11 eyes from 7 patients. Intraocular pressure was reduced from 33 to 18 mm Hg, at a mean of 11 months after surgery. The most common complication was transient hyphema, whereas 80% to 90% of procedures were considered a success. 69 To assess whether modern surgical techniques such as IOL placement influence the incidence of glaucoma in children with congenital cataracts, the Infant Aphakia Treatment Study Group monitored children who had been randomized to receive cataract extraction with or without IOL placement. The authors found that 14 (12%) of 114 patients had a glaucoma-related adverse event, with 16% experiencing these events after lensectomy and anterior vitrectomy. The presence of persistent fetal vasculature tripled the likelihood of glaucoma, and for each month that the surgery was performed earlier, the likelihood of glaucoma increased by 60%. 70 
MOLECULAR BIOLOGY IN GLAUCOMA
Pieragostino et al 71 used liquid chromatographyYmass spectrometry to demonstrate differences in the levels of lysozyme C, lipocalin-1, protein S100, immunoglobulins, and prolactininducible protein in the tears of patients with and without glaucoma. Furthermore, they found that POAG and pseudoexfoliation glaucoma can be distinguished based on the expression of phosphorylated cystatin-S. 71 Based on the notion that glaucoma may be mediated by proinflammatory monocytes, Howell et al 72 reported that a singledose of x-ray treatment is able to prevent the migration of monocytes into the optic nerve and subsequently prevent the progression of glaucomatous damage in a mouse model of glaucoma.
Other factors believed to contribute to glaucomatous progression include adenylate-uridylateYrich elements, such as interleukin 6 and interleukin 8, which Mochizuki et al 73 found to be stabilized by the induction of oxidative stress on human trabecular meshwork cells in vitro, suggesting another potential mechanism of progression.
Multiple studies have also investigated specific molecules and pathways that directly regulate IOP and indirectly modulate glaucoma progression. For instance, Bucolo et al 73 treated mice topically with 7-hydroxy-2-N,N-dipropylaminotetralin, a synthetic dopamine D3-receptor agonist, and showed that these mice exhibit a significant decrease in IOP. This IOP-lowering effect was not observed in mice that had been treated with a D3receptor antagonist or in knockout mice not expressing genes for the D3-receptor, supporting a mechanism of action through the dopamine pathway. 74 In addition, Junglas et al 75 examined the effects of connective tissue growth factor when overexpressed in mouse eyes, based on the premise that transforming growth factor-A2 can mediate the increase in outflow resistance ultimately leading to POAG. They found that connective tissue growth factor induces changes within the actin cytoskeleton of cultured trabecular meshwork cells in vitro, which was accompanied by an increase in IOP and subsequent optic nerve damage in vivo. 75 Similarly, Sun et al 76 used an ocular hypertension model in rats to assess the effect of the sigma receptor agonist, pregnenolone sulfate, on IOP. They found that pregnenolone significantly decreased IOP, prevented ganglion cell loss, protected inner plexiform layer thickness, and increased sigma receptor 1 expression, leading the group to speculate that activation of the sigma receptor pathway may have neuroprotective properties. 76 To assess the potential role of nitric oxide (NO) in IOP regulation, Stamer et al 77 used transgenic mice overexpressing endothelial NO synthase to show that these mice have lower IOP and increased pressure-dependent drainage compared with wild types. This effect was reversed by the NO synthase inhibitor, L-NG-nitroarginine methyl ester. 77 Other studies have investigated the potential of a sustained drug delivery system. For example, Natarajan et al 78 incorporated latanoprost into large unilamellar vesicles, which they demonstrated possessed good stability during storage and release. They were able to show that a single subconjunctival injection of their formulation into rabbits was able to lower IOP for up to 50 days, with a magnitude similar to that seen with daily drop adminstration. 78 The group then developed a liposomal nanocarrier for sustained release of latanoprost into rabbit eyes. Their formulation consisted of latanoprost-loaded egg-phosphatidylcholine liposomes, roughly 110 nm, which were stable at 25-C for at least 1 month. They showed that for 90 days, the sustained delivery latanoprost demonstrated a stronger IOP-lowering effect than daily administration of topical latanoprost [mean (SD), 4.8 (1.5) mm Hg vs 2.5 (0.9) mm Hg; P G 0.001]. 79 Du et al 80 investigated human trabecular meshwork stem cells to determine their multipotency and measured differential gene expression with quantitative reverse transcriptase polymerase chain reaction, immunostaining, and immunoblotting. They ultimately determined that trabecular meshwork stem cells exhibit multipotent ability of differentiation into a variety of cell types, including phagocytic trabecular meshwork cells. 80
CONCLUSIONS
The studies outlined above represent only a small fraction of the research articles published over the course of the 2011Y2012 academic year. Nevertheless, these studies exhibit great potential in enhancing our understanding, characterization, and treatment of patients with glaucoma. For instance, technological advancements in optic nerve imaging combined with novel statistical methods of analyzing data obtained from perimetry have helped researchers better characterize the diagnosis and progression of glaucoma, while a multitude of prospective randomized trials have come to bear insight into optimizing the surgical and medical management of glaucoma patients. Most importantly, these articles have raised new questions and ideas that will undoubtedly serve as the impetus for continued progress and development in the field of glaucoma research.
